IGF2 and adrenal cortex carcinoma: Moreover, the use of hydroxytamoxifen, an active metabolite of the oestrogen antagonist tamoxifen, decreases IGF1R expression and counteract E2‐ and IGF‐II‐induced ACC cell growth, both in vitro and in vivo.8